PE20231383A1 - 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 - Google Patents

2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8

Info

Publication number
PE20231383A1
PE20231383A1 PE2022002927A PE2022002927A PE20231383A1 PE 20231383 A1 PE20231383 A1 PE 20231383A1 PE 2022002927 A PE2022002927 A PE 2022002927A PE 2022002927 A PE2022002927 A PE 2022002927A PE 20231383 A1 PE20231383 A1 PE 20231383A1
Authority
PE
Peru
Prior art keywords
alkyl
alkynyl
alkenyl
aryl
methyl
Prior art date
Application number
PE2022002927A
Other languages
English (en)
Inventor
Ashok Arasappan
Ian M Bell
Christopher James Bungard
Christopher S Burgey
Jason M Cox
Iii Michael J Kelly
Mark E Layton
Hong Liu
Jian Liu
James J Perkins
Akshay A Shah
Michael David Vanheyst
Zhe Wu
Original Assignee
Merck Sharp And Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp And Dohme Llc filed Critical Merck Sharp And Dohme Llc
Publication of PE20231383A1 publication Critical patent/PE20231383A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta referido a derivados de 2-oxoimidazolidin-4-carboxamidas de Formula I, en donde: uno de A y B es arilo o heteroarilo, cualquiera de ellos opcionalmente sustituidos con Ra, y el otro de A y B es arilo, heteroarilo, alquil C1-6-arilo, cicloalquil C3-8-arilo, entre otros; R1 es H, alquilo C1-6, alquenilo C3-6, alquinilo C3-6, entre otros; R2 es H, alquenilo C3-6, entre otros; R3 es H, alquinilo C2-6, cicloalquilo C3-10, cicloheteroalquilo C2-10, entre otros; R4 es H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, entre otros; R5 es H o alquilo C1-6 opcionalmente sustituido con halogeno; R6 es H, cicloalquilo C3-6, cicloheteroalquilo C2-6, entre otros; y, R7 es H, alquilo C1-6, alquenilo C2-6, o alquinilo C2-6, cualquiera de ellos opcionalmente sustituido con halogeno. Entre los compuestos preferidos tenemos los siguientes: (S)-N-((R)-2-(3-cloro-4-fluorofenoxi)-1-(3-cloro-4-fluorofenil)etil)-2- oxoimidazolidin-4-carboxamida; (R)-N-(bis(4-clorofenil)metil)-3-metil-2-oxoimidazolidin-4-carboxamida y (S)-N-(bis(4-clorofenil)metil)-3-metil-2-oxoimidazolidin-4-carboxamida; entre otros. Estos compuestos son inhibidores de la actividad de los canales de sodio de Nav1.8 (o inhibidores de Nav1.8) y pueden ser utiles en el tratamiento y prevencion de enfermedades, trastornos y afecciones mediadas por la actividad de los canales de sodio de Nav1.8, tales como nocicepcion, osteoartritis, esclerosis multiple, asma, picazon, dermatitis alergica o de contacto, insuficiencia renal, dolor, entre otros.
PE2022002927A 2020-06-17 2021-06-15 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 PE20231383A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040461P 2020-06-17 2020-06-17
PCT/US2021/037303 WO2021257490A1 (en) 2020-06-17 2021-06-15 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors

Publications (1)

Publication Number Publication Date
PE20231383A1 true PE20231383A1 (es) 2023-09-12

Family

ID=76829646

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002927A PE20231383A1 (es) 2020-06-17 2021-06-15 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8

Country Status (19)

Country Link
US (2) US11802122B2 (es)
EP (1) EP4168393A1 (es)
JP (3) JP7323723B2 (es)
KR (1) KR20230024985A (es)
CN (1) CN116134018A (es)
AR (1) AR122628A1 (es)
AU (1) AU2021293176A1 (es)
BR (1) BR112022025805A2 (es)
CA (1) CA3182633A1 (es)
CL (1) CL2022003544A1 (es)
CO (1) CO2022018295A2 (es)
CR (1) CR20220642A (es)
DO (1) DOP2022000290A (es)
EC (1) ECSP23003443A (es)
IL (1) IL299180A (es)
MX (1) MX2022015581A (es)
PE (1) PE20231383A1 (es)
TW (1) TWI806073B (es)
WO (1) WO2021257490A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI827037B (zh) * 2021-05-07 2023-12-21 美商默沙東有限責任公司 作為nav1.8抑制劑之環烷基3-側氧基哌甲醯胺及環雜烷基3-側氧基哌甲醯胺
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
JP2024522293A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしての置換テトラヒドロフラン類似体
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CA3222197A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202408501A (zh) 2022-04-22 2024-03-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008234855B2 (en) * 2007-04-03 2011-01-20 Glaxo Group Limited Imidazolidine carboxamide derivatives as P2X7 modulators
WO2009049180A2 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
JP5436434B2 (ja) 2007-10-11 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアミド
NZ584519A (en) 2007-10-11 2012-07-27 Vertex Pharma Aryl amides useful as inhibitors of voltage-gated sodium channels
US8629149B2 (en) 2009-09-04 2014-01-14 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
MY157429A (en) 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
CA2839703A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
RS56015B1 (sr) 2013-01-31 2017-09-29 Vertex Pharma Piridon amidi kao modulatori natrijumovih kanala
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
WO2014120820A1 (en) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
WO2014146111A2 (en) * 2013-03-15 2014-09-18 The Regents Of The University Of California Analgesic compounds and methods of use
US11203571B2 (en) 2013-07-19 2021-12-21 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
CN108395452B (zh) 2013-12-13 2021-08-03 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
CN109153659A (zh) 2016-05-31 2019-01-04 翰林大学产学研合作团队 五元杂环衍生物、其制备方法及包含其的药剂学组合物
CA3063901A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
UY37806A (es) 2017-07-11 2020-01-31 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
CN111601798B (zh) * 2017-09-13 2023-08-11 美国安进公司 双酰胺肌节活化化合物及其用途
SG11202104326TA (en) * 2018-11-02 2021-05-28 Merck Sharp & Dohme 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors

Also Published As

Publication number Publication date
JP2023093623A (ja) 2023-07-04
US11802122B2 (en) 2023-10-31
CO2022018295A2 (es) 2022-12-20
ECSP23003443A (es) 2023-02-28
IL299180A (en) 2023-02-01
KR20230024985A (ko) 2023-02-21
DOP2022000290A (es) 2023-01-31
WO2021257490A1 (en) 2021-12-23
CR20220642A (es) 2023-02-15
JP7323723B2 (ja) 2023-08-08
EP4168393A1 (en) 2023-04-26
CL2022003544A1 (es) 2023-06-02
CA3182633A1 (en) 2021-12-23
US20230312528A1 (en) 2023-10-05
JP2023139235A (ja) 2023-10-03
CN116134018A (zh) 2023-05-16
JP2023524167A (ja) 2023-06-08
AU2021293176A1 (en) 2023-02-02
US20210403457A1 (en) 2021-12-30
BR112022025805A2 (pt) 2023-01-10
MX2022015581A (es) 2023-01-24
TWI806073B (zh) 2023-06-21
TW202214573A (zh) 2022-04-16
AR122628A1 (es) 2022-09-21

Similar Documents

Publication Publication Date Title
PE20231383A1 (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
CA2574600A1 (en) Pyridine derivatives
PE20091065A1 (es) Derivados bis-(sulfonilamino) en terapia 066
PE20131117A1 (es) Derivados de bencimidazol como inhibidores de prostaglandinas
PE20110285A1 (es) Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
RU2013114771A (ru) Диамиды азетидинила как ингибиторы моноацилглицерол липазы
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
PE20070712A1 (es) Sulfonamidas biciclicas como moduladores del receptor de glucocorticoides en el tratamiento de enfermedades inflamatorias
PE20160891A1 (es) Moduladores de ror gamma (rory)
PE20091398A1 (es) Compuestos biciclicos conteniendo nitrogeno activos en condiciones de dolor cronicas
PE20211049A1 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
RS52155B (en) PYROLO (3,4-c) PIRAZOL DERIVATIVE ACTIVE AS KINASE INHIBITORS
PE20201256A1 (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
EA201001414A1 (ru) Производные азетидина и их применение
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
JP2017516796A5 (es)
MX2020009235A (es) Formulacion oftalmica.
PE20081657A1 (es) Derivados de ftalazina como antagonistas de los receptores de histamina h1
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
PE20211733A1 (es) Amidas de pirrolidina sustituidas